Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07526545 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

Study acronym: UPRISE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Mar 1, 2030 → Jun 1, 2030
See other at-risk trials from University of Michigan Rogel Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date: Sep 1, 2026 to Dec 1, 2026
    • Primary and study completion pushed from Mar 1, 2030 to Jun 1, 2030
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 6 entries
    • Site details revised
  2. Start date: May 1, 2026 to Sep 1, 2026
    • Primary and study completion pushed from Nov 1, 2029 to Mar 1, 2030
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Trial Details
NCT Number NCT07526545
Lead Sponsor University of Michigan Rogel Cancer Center
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Conditions
(from sponsor)		 Prostate Carcinoma
Related terms Prostatic Neoplasms
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov